Filtered By:
Drug: Clopidogrel

This page shows you your search results in order of relevance. This is page number 12.

Order by Relevance | Date

Total 1913 results found since Jan 2013.

Efficacy and Safety of Using Dual Versus Monotherapy Antiplatelet Agents in Secondary Stroke Prevention: Systematic Review and Meta-Analysis of Randomized Controlled Clinical Trials
Conclusions: DAPT decreases the risk of recurrent stroke and composite events compared with monotherapy. DAPT increases the risk of major hemorrhage, except if the treatment is limited to 30 days and does not include the combination of aspirin plus ticagrelor.PMID:33926204 | DOI:10.1161/CIRCULATIONAHA.121.053782
Source: Circulation - April 30, 2021 Category: Cardiology Authors: Gabriela Trifan Philip B Gorelick Fernando D Testai Source Type: research

The Clinical Efficacy of Clopidogrel Bisulfate Tablets Combined with Olmesartan Medoxomil for Ischemic Stroke with Hypertension and the Effect of Angiotensin II Type 1 Receptor Level on Prognosis
CONCLUSION: Clopidogrel bisulfate tablets combined with olmesartan medoxomil has prominent clinical effects in the treatment of ischemic stroke patients with hypertension, evidently improving the prognosis. In addition, the level of AT1R may be a vital factor affecting the prognosis.PMID:34745325 | PMC:PMC8566065 | DOI:10.1155/2021/4487393
Source: Computational and Mathematical Methods in Medicine - November 8, 2021 Category: Statistics Authors: Jia Yu Wei Fang Xing Guo Haiyang Jiang Peng Sun Yufeng Liu Xin Jin Source Type: research

Efficacy and safety of clopidogrel and/or aspirin for ischemic stroke/transient ischemic attack: An overview of systematic reviews and meta-analysis
Conclusions: High-quality evidence suggested that clopidogrel plus aspirin was more efficient than monotherapy, although the risk for hemorrhagic stroke was relatively higher in combined therapy regimens lasting>1 month.
Source: Medicine - December 17, 2021 Category: Internal Medicine Tags: Research Article: Systematic Review and Meta-Analysis Source Type: research

Stroke Prevention in Symptomatic Large Artery Intracranial Atherosclerosis Practice Advisory: Report of the AAN Guideline Subcommittee
Neurology. 2022 Mar 22;98(12):486-498. doi: 10.1212/WNL.0000000000200030.ABSTRACTBACKGROUND AND OBJECTIVES: To review treatments for reducing the risk of recurrent stroke or death in patients with symptomatic intracranial atherosclerotic arterial stenosis (sICAS).METHODS: The development of this practice advisory followed the process outlined in the American Academy of Neurology Clinical Practice Guideline Process Manual, 2011 Edition, as amended. The systematic review included studies through November 2020. Recommendations were based on evidence, related evidence, principles of care, and inferences.MAJOR RECOMMENDATIONS: ...
Source: Atherosclerosis - March 22, 2022 Category: Cardiology Authors: Tanya N Turan Osama O Zaidat Gary S Gronseth Marc I Chimowitz Antonio Culebras Anthony J Furlan Larry B Goldstein Nestor R Gonzalez Julius G Latorre Steven R Mess é Thanh N Nguyen Rajbeer S Sangha Michael J Schneck Aneesh B Singhal Lawrence R Wechsler Al Source Type: research

P2Y12 inhibitors plus aspirin for acute treatment and secondary prevention in minor stroke and high-risk transient ischemic attack: A systematic review and meta-analysis
CONCLUSIONS: Early administration of P2Y12 inhibitors plus aspirin in patients with acute non-cardioembolic minor ischemic stroke or TIA reduced the incidence of ischemic stroke recurrence, impacting more significantly than the increased bleeding risk and influencing patients' quality of life by reducing disabling stroke.PMID:35331593 | DOI:10.1016/j.ejim.2022.03.017
Source: European Journal of Internal Medicine - March 25, 2022 Category: Internal Medicine Authors: Fulvio Pomero Eleonora Galli Marta Bellesini Lorenzo Maroni Alessandro Squizzato Source Type: research

Antiplatelet regimens after ischemic stroke or transient ischemic attack: a systematic review and updated network meta-analysis
CONCLUSIONS: The efficacy and safety profiles among antiplatelet regimens may differ according to clinical situation, although cilostazol, aspirin plus clopidogrel, and aspirin plus dipyridamole may be considered as preferable options.PMID:35402589 | PMC:PMC8987873 | DOI:10.21037/atm-21-3748
Source: Atherosclerosis - April 11, 2022 Category: Cardiology Authors: Seung Jin Jung Bum Joon Kim Chi Kyung Kim Sung Ryul Shim Jin-Man Jung Source Type: research

Associations of CYP2C19 and F2R genetic polymorphisms with platelet reactivity in Chinese ischemic stroke patients receiving clopidogrel therapy
Conclusions Together, these results emphasized the necessity of genotype-directed antiplatelet therapy and facilitated to minimize adverse ischemic events.
Source: Pharmacogenetics and Genomics - May 13, 2022 Category: Genetics & Stem Cells Tags: Original Articles Source Type: research

No rebound effect after a course of clopidogrel in patients with acute TIA or minor stroke
CONCLUSIONS: No rebound increase in the risk of ischemic stroke and composite events was found during the 90 days after discontinuation of clopidogrel therapy in patients with TIA or minor stroke in the CHANCE trial.TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT00979589.PMID:35695332 | DOI:10.1080/01616412.2022.2075660
Source: Neurological Research - June 13, 2022 Category: Neurology Authors: Xinmiao Zhang Jing Jing Xingquan Zhao Liping Liu Anxin Wang Yuesong Pan David Wang S Claiborne Johnston Yilong Wang Yongjun Wang Xia Meng Source Type: research